Infant Pulmonary Disorders
Infant Pulmonary Disorders

Infant Pulmonary Disorders

The Center for Infant Pulmonary Disorders at Children’s Mercy Kansas City is a recognized leader in researching and improving treatments for chronic lung diseases in infants.

Our team is involved with ongoing studies to discover new treatment methods that improve quality of life for newborns with pulmonary conditions.

We focus on improving infant health by partnering with other neonatologists as well as specialists in pulmonology, immunology, pharmacology, outcomes research and other disciplines. The support provided by the center blends with and supplements new and ongoing externally funded clinical and translational research. 

Faculty and Staff

William E. Truog
Director of the Center for Infant Pulmonary Disorders; Sosland Chair in Neonatal Research; Professor of Pediatrics, University of Missouri-Kansas City School of Medicine

Center Manager

Michael Norberg

Neonatal Business and Academic Manager

Betsi Anderson

Research Grants and Initiatives

The center continually pursues new studies which combine in-depth research and potentially effective clinical treatments to minimize the short-term and lifelong effects of pulmonary disorders. Our team also provides long-term follow-up assessments to help maintain long-term health.

The Center for Infant Pulmonary Disorders is involved with many research initiatives and supported through grants and endowments. These ongoing research efforts are leading to new treatment breakthroughs for infants with chronic pulmonary disorders.

Current External Research Grants

  • >NIH/NHLBI U-O1HL94338 TOLSURF (Late Surfactant) RCT Multicenter Clinical Trial Network to Test the Role of "Late" Surfactant in Infants (2009-2014)
    Overall principal investigator: R.A. Ballard, MD (UCSF-SOM)
    Local principal investigator and steering committee member: W.E. Truog, MD
  • NICHD NRN U-10 HD068284 Children's Mercy-Truman-UMKC Center: A New Addition for the Next Five Years (2011-2016)
    This cooperative grant builds on existing areas of excellence at Children's Mercy Kansas City including the Fetal Health Center, the Neonatal Extracorporeal Membrane Oxygenation program, the Center for Infant Pulmonary Disorders, the infant home ventilator program, the ongoing federal and other externally funded clinical research, and our demonstrated excellent clinical outcomes.
    Principal investigator: W.E. Truog, MD

Special Endowments

  • Cooper Connor Endowed Fund for Pulmonary Research
  • Sosland Family Endowed Chair in Neonatal Research

Peer-Reviewed Publications

  • Nyp MF, Taylor JB, Norberg M, Truog WE.  Impaired growth at birth and bronchopulmonary dysplasia classification: beyond small for gestational age. Am J Perinatol. (2014)
  • Taylor JB, Nyp MF, Norberg M, Dai H, Escobar H, Ellerbeck E, Truog WE. Impact of intercurrent respiratory infections on lung health in infants born <29 weeks with bronchopulmonary dysplasia. J Perinatol. 34(3):223-228 (2014)
  • Truog WE, Nyp MF, Taylor J, Gratny LL, Escobar H, Manimtim WM, Lachica CI, Khmour A, Oluola OO, Oshodi AA, Norberg M, Dai H, Pallotto EK. Infants born at <29 weeks: pulmonary outcomes from a hybrid perinatal system. J Perinatol. 34(1):59-63 (2014)
  • Keller R, Merrill JD, Black DM, Steinhorn RH, Eichenwald EC, Durand DJ, Ryan RM, Truog WE, Courtney SE, Ballard PL, Ballard RA. Late administration of surfactant replacement therapy increasessurfactant protein-B content: a randomized pilot study. Pediatr Res. 72(6):613-619 (2012)
  • Nyp M, Sandritter T, Poppinga N, Simon C, Truog WE. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange:any benefits? J Perinatol. 32(1):64-69 (2012)
  • Merrill JD, Ballard PL, Courtney SE, Durand, DJ, Hamvas A, Hibbs AM, Lu KW, Ryan RM, Reynolds AM, Spence K, Steinhorn RH, Truog WE, Eichenwald EC, Ballard RA.  Pilot trial of latebooster doses of surfactant for ventilated premature infants. J Perinatol. 31:599-606 (2011)
  • Petrikin JE, Gaedigk R, Leeder JS, Truog WE. Selective toll-like receptor expression in human fetal lung. Pediatr Res 68(4):335-338 (2010)
  • Truog WE. 21stCentury Use for Surfactant? (editorial) Pediatrics. 123:173 (2009)

Other Activities

  • Maintenance of a chronic lung disease team in the Children's Mercy Neonatal Intensive Care Unit (NICU) that supports increased and earlier referrals of patients with complex lung and airway problems
  • Support of the Children's Mercy Home Infant Ventilator Program
  • Creation of comprehensive data repository for clinical trial projects
  • Follow-up study of pulmonary function/exercise testing of a cohort of 6-10 year old children from prior research protocol
  • Researching new uses of surfactant for treating infant pulmonary disorders

Copyright © 1996-2016 The Children's Mercy Hospital